Reata Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>RP</div>
RETA -- USA Stock  

USD 101.31  3.90  3.71%

As many of us are excited about healthcare space, it is fair to go over Reata Pharmaceuticals within current market trends. As expected, Reata Pharmaceuticals is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on investing in Reata Pharmaceuticals and the market returns of the last few months appear uncorrelated. Weak basic indicators of the company may also suggest signs of long term losses for Reata investors. Reata Pharmaceuticals is scheduled to announce its earnings today. The next earnings report is expected on the 10th of November 2020. The stock is undergoing an active downward rally.
Published over a month ago
View all stories for Reata Pharmaceuticals | View All Stories
Will Reata Pharmaceuticals (NASDAQ:RETA) price continue to rise in September?
Reata Pharmaceuticals's average rating is Buy from 9 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Reata Pharmaceuticals market sentiment investors' perception of the future value of Reata. Let us look at a few aspects of Reata technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Reata Pharmaceuticals. In general, we focus on analyzing Reata Pharmaceuticals stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Reata Pharmaceuticals's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Reata Pharmaceuticals's intrinsic value. In addition to deriving basic predictive indicators for Reata Pharmaceuticals, we also check how macroeconomic factors affect Reata Pharmaceuticals price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Reata Stands against Peers?

Analyzing Reata Pharmaceuticals competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Reata Pharmaceuticals across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Reata Pharmaceuticals Competition Details

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Reata Pharmaceuticals, but it might be worth checking our own buy vs. sell analysis

Purchase by Soni Manmeet Singh of 1000 shares of Reata Pharmaceuticals

Legal trades by Reata Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Reata insider trading alert for perchase of class a common stock by Soni Manmeet Singh, COO and CFO, on 14th of August 2020. This event was filed by Reata Pharmaceuticals Inc with SEC on 2020-08-14. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Reata Pharmaceuticals Standard Deviation

Reata Pharmaceuticals has current Standard Deviation of 4.59. The Standard Deviation is a measure of how spread out the prices or returns of an asset are on average. It is the most widely used risk indicator in the field of investing and finance. Standard Deviation is commonly used to measure confidence in statistical conclusions regarding certain equity instruments or portfolios of equities.

Standard deviation is applied to the annual rate of return of an investment to measure the investment's volatility. Standard deviation is also known as historical volatility and is used by investors as a gauge for the amount of expected market volatility. A large standard deviation usually indicates that the data points are far from the mean and a small standard deviation indicates that they are clustered closely around the mean.

Standard Deviation 
=  
SQRT(V) 
 = 
4.59
SQRT = Square root notation
V =   Variance of Reata Pharmaceuticals returns
Let's now compare Reata Pharmaceuticals Standard Deviation to its closest peers:
RETA
INCY
SBMFF
ALXN
TECH
RETA4.590108561653113
INCY2.53
SBMFF5.09
ALXN2.29
TECH2.18

Will Reata Pharmaceuticals growth be viable after the rise?

Current maximum drawdown is at 33.74. Reata Pharmaceuticals shows above-average downside volatility for the selected time horizon. We advise investors to inspect Reata Pharmaceuticals further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Reata Pharmaceuticals future alpha.

The Bottom Line

When is the right time to buy or sell Reata Pharmaceuticals? Buying stocks such as Reata Pharmaceuticals isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. Taking everything into account, as of the 10th of August 2020, our primary 30 days recommendation on the company is Sell. However, we believe Reata Pharmaceuticals is currently undervalued with very low chance of bankruptcy for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Reata Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com